Table 10.
Logistic Regression Analysis for Aldosterone at Visit 1 and Cardiac Structure and Function at Visit 2
| Outcome (Total N/New Event N) | OR (95% CI) Per 1 SD Increase in log Aldo | P Value | OR (95% CI) Top Tertile vs Bottom 2 Tertiles of Aldo | P Value |
|---|---|---|---|---|
| New HF (N=1125/12) | ||||
| Age, sex, BMI (base) | 1.03 (0.60, 1.77) | 0.920 | 1.83 (0.57, 5.84) | 0.308 |
| Base+NT‐proANP | 1.13 (0.65, 1.98) | 0.658 | 2.40 (0.69, 8.32) | 0.168 |
| Base+ANP | 1.12 (0.64, 1.96) | 0.698 | 2.33 (0.67, 8.03) | 0.182 |
| Base+NT‐proBNP | 1.07 (0.59, 1.93) | 0.830 | 2.53 (0.71, 8.95) | 0.150 |
| Base+BNP | 1.22 (0.68, 2.18) | 0.512 | 2.91 (0.85, 9.99) | 0.090 |
| Base+GFR | 1.05 (0.60, 1.82) | 0.866 | 1.90 (0.59, 6.09) | 0.282 |
| New c‐LVH (N=775/46) | ||||
| Age, sex, BMI (base) | 1.10 (0.81, 1.49) | 0.540 | 1.05 (0.54, 2.02) | 0.892 |
| Base+NT‐proANP | 1.13 (0.83, 1.54) | 0.433 | 1.12 (0.58, 2.18) | 0.740 |
| Base+ANP | 1.10 (0.81, 1.50) | 0.530 | 1.03 (0.54, 2.00) | 0.920 |
| Base+NT‐proBNP | 1.09 (0.80, 1.49) | 0.578 | 1.08 (0.55, 2.10) | 0.830 |
| Base+BNP | 1.15 (0.85, 1.57) | 0.368 | 1.15 (0.59, 2.22) | 0.684 |
| Base+antihypertensives | 1.04 (0.76, 1.42) | 0.796 | 0.95 (0.48, 1.87) | 0.876 |
| Base+GFR | 1.14 (0.83, 1.55) | 0.415 | 1.09 (0.56, 2.11) | 0.804 |
| New DDF (mild/moderate/severe) (N=790/262) | ||||
| Age, sex, BMI (base) | 1.15 (0.95, 1.39) | 0.545 | 1.25 (0.84, 1.86) | 0.781 |
| Base+NT‐proANP | 1.09 (0.90, 1.33) | 0.550 | 1.12 (0.75, 1.68) | 0.969 |
| Base+ANP | 1.15 (0.94, 1.39) | 0.384 | 1.22 (0.82, 1.83) | 0.654 |
| Base+NT‐proBNP | 1.13 (0.93, 1.38) | 0.569 | 1.28 (0.85, 1.92) | 0.745 |
| Base+BNP | 1.15 (0.95, 1.39) | 0.537 | 1.25 (0.84, 1.86) | 0.775 |
| Base+antihypertensives | 1.12 (0.91, 1.38) | 0.630 | 1.20 (0.78, 1.84) | 0.553 |
| Base+GFR | 1.10 (0.90, 1.34) | 0.542 | 1.17 (0.78, 1.76) | 0.834 |
| New EF <40% (N=1132/10) | ||||
| Age, sex, BMI (base) | 1.13 (0.63, 2.01) | 0.691 | 1.77 (0.50, 6.25) | 0.374 |
| Base+NT‐proANP | 1.13 (0.63, 2.02) | 0.683 | 1.80 (0.51, 6.39) | 0.361 |
| Base+ANP | 1.14 (0.64, 2.06) | 0.654 | 1.88 (0.53, 6.71) | 0.332 |
| Base+NT‐proBNP | 1.18 (0.66, 2.13) | 0.581 | 1.94 (0.54, 6.98) | 0.308 |
| Base+BNP | 1.21 (0.67, 2.20) | 0.524 | 2.06 (0.57, 7.39) | 0.268 |
| Base+antihypertensives | 0.97 (0.54, 1.74) | 0.908 | 1.39 (0.38, 5.09) | 0.618 |
| Base+GFR | 1.13 (0.63, 2.03) | 0.678 | 1.80 (0.51, 6.37) | 0.364 |
Results of logistic regression analysis, covariates taken from Visit 1. ANP indicates atrial natriuretic peptide; BMI, body mass index; BNP, B type natriuretic peptide; c‐LVH, concentric left ventricular hypertrophy; DDF, diastolic dysfunction; EF, ejection fraction; GFR, glomerular filtration rate; HF, chronic heart failure; NT‐proANP, N‐terminus of pro‐atrial natriuretic peptide; NT‐proBNP, N‐terminus of pro‐B type natriuretic peptide; OR, odds ratio.